Aptose Biosciences Inc. (APTOF): Nasdaq/NYSE listing notice — Aptose receives Nasdaq deficiency notice for stock issuance without shareholder approval

Aptose Biosciences Inc.

Nasdaq notified Aptose on Feb 29, 2024 that the Hanmi stock issuance violated Rule 5635(d) by issuing >20% of common shares at a discount without shareholder approval.
Company has 45 days, until April 14, 2024, to submit a plan to regain compliance.
If Nasdaq accepts the plan, an extension of up to 180 days from the deficiency letter may be granted.
No immediate effect on listing; APTO continues trading on Nasdaq and TSX under symbol APS.
Aptose believes the transaction complied with rules and intends to work with Nasdaq, but no assurance of regaining compliance.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(d)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5635(d)

Exact text from the filing

February 29, 2024, Aptose Biosciences Inc. (the “Company”) received a deficiency letter (the “Deficiency Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company’s recent issuance of securities to Hanmi Pharmaceutical Co., Ltd. (the “Hanmi Transaction”) violated 5635(d) because the Company did not obtain shareholder approval prior to such issuance. Nasdaq stated that completion of the Hanmi Transaction involved the issuance of greater than 20% of the issued and outstanding common shares of the Company at a disco

View on SEC.gov

Browse all listing & compliance notices →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-001127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.